Board of Directors

Dr. Xu has served on the Board of Directors since March 2016. In November 2017, the board of directors elected Dr. Xu as president and chief executive officer (transitioning from interim chief executive officer as of November 2016; he joined the board of directors in March 2016 and currently serves as chairman of the board).  He brings over 15 years of leadership experience in the biopharmaceutical industry and has contributed to numerous successful product launches. In 2009, Dr. Xu founded Boyalife Group, a global diversified life sciences holding company and is currently the principal shareholder of ThermoGenesis Holdings, Inc. Prior to founding Boyalife, Dr. Xu served as a project leader at Pfizer, as a director of research at two publicly-traded companies and as a vice president at Founder Group, a technology conglomerate with $20 billion annual revenue. Dr. Xu’s expertise spans several diverse therapeutic areas, including arthritis & inflammation, cardiovascular disease, autoimmunity, oncology and diabetes. He has authored over forty publications and has been recognized by numerous professional societies for his contributions to biomedical research. Dr. Xu received his Ph.D. in immunology from Washington University School of Medicine (St. Louis, USA) and an executive MBA from Emory University (Atlanta, USA).

Ms. Donaghy was appointed to the Board of Directors in December 2019.  Ms. Donaghy has served in various positions at CTI Foods, LLC from May 2017 until February 2019, most recently as Vice President, Corporate Controller.  Before that, she served for over 15 years in roles of increasing responsibility for Diamond Foods, Inc., most recently as the Vice President Shared Services and earlier as Assistant Corporate Controller, Senior Director of Internal Audit and Senior Director of Finance and Treasury. Prior, Ms. Donaghy was Director of Treasury and Cash Management at E. & J. Gallo Winery having also served as Director of Financial Services and Manager of Financial Reporting.  Ms. Donaghy is a Certified Public Accountant. She earned a master’s degree in taxation from Gonzaga University, and her undergraduate degree in accounting and business management from Whitworth College. Ms. Donaghy is one of our independent directors pursuant to applicable NASDAQ rules and is qualified as an Audit Committee Financial Expert as defined in Regulation S-K Item 407(d)(5)(ii).

Dr. Thomis was appointed to the Board of Directors in January 2017. He brings more than 40 years of experience in drug discovery, clinical development and commercialization. After a short period in academia, Dr. Thomis played a major role in the development and registration of eight commercially successful cardiovascular and infectious disease products while at Bristol-Myers Squibb. He has also held senior clinical development roles at Quintiles, a global provider of pharmaceutical services, where he was instrumental in the growth of clinical research in Europe. He also specialized in designing and implementing effective regional and global clinical strategies as well as repositioning and restructuring organizations. Dr. Thomis is currently a non-executive Director at NovaQuest LLC, a private equity company and Chairman of the Board of Quotient Sciences, a translational pharmaceutics company. He is also Chairman of WP Clinical, a private company, offering access services in unlicensed medicines. He previously served on the EMEA and American management boards of Quintiles as well as on the board of PDP Courier Services and Idis Group Holdings. Dr. Thomis is one of our independent directors pursuant to applicable NASDAQ rules.

Dr. Medford was appointed to the Board in February 2017. He is a managing partner of the Salutramed Group, LLC, a life sciences management consultancy, and has extensive private and public company expertise. He also serves as chief executive officer of healthEgames, Inc., a digital healthcare company and serves as the executive chairman of ViaMune, Inc., an immuno-oncology company. Dr. Medford has served as the co-founder, president, chief executive officer and director of AtheroGenics, Inc. and was a founding board member of Inhibitex, Inc., serving on its board until its acquisition by Bristol-Myers Squibb in 2012. He has led companies through multiple stages of research and development, advancing novel, first-in-man clinical candidates for the treatment of cardiovascular disease, diabetes and arthritis. Dr. Medford obtained his M.D. and Ph.D. from the Albert Einstein College of Medicine. Dr. Medford is one of our independent directors pursuant to applicable NASDAQ rules and is qualified as an Audit Committee Financial Expert as defined in Regulation S-K Item 407(d)(5)(ii).

How may we help?